https://www.selleckchem.com/ATM.html
These findings establish a preclinical proof of concept for combating CC by dual targeting of JAK1/2 and DNMT1, and provide support for launching a clinical trial to evaluate the efficacy and safety of this drug combination in patients with CC and other malignant tumors. An online survey. To describe how healthcare providers manage depression after spinal cord damage (SCD) and to identify factors that predict use of recommended depression management practices. An international cohort of respondents who provide clinical care to individuals with SCD.
Like
Comment
Share
